Hokushin
7897
Omikenshi
3111
OncoTherapy Science
4564
DREAM VISION
3185
Axel Mark
3624
(Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | (Q3)Jan 31, 2023 | (Q2)Oct 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -40.30%5.75B | -25.52%32.02B | -15.62%6.42B | -22.88%6.8B | -38.35%9.17B | -17.63%9.63B | 5.01%43B | -17.85%7.61B | -18.15%8.82B | 44.93%14.88B |
Cost of revenue | -34.85%2.34B | -23.47%12.9B | -1.71%2.95B | -15.60%2.81B | -40.80%3.54B | -20.79%3.59B | 6.32%16.85B | -14.16%3B | -21.22%3.33B | 41.43%5.98B |
Gross profit | -43.55%3.41B | -26.84%19.13B | -24.70%3.47B | -27.29%3.99B | -36.70%5.63B | -15.62%6.04B | 4.19%26.15B | -20.09%4.6B | -16.16%5.49B | 47.39%8.9B |
Operating expense | -26.41%3.21B | -6.50%18.71B | 17.17%4.9B | -14.62%4.39B | -4.84%5.06B | -18.77%4.36B | 9.87%20.01B | -14.47%4.18B | 15.20%5.15B | 5.45%5.31B |
Staff costs | 6.49%458M | 10.63%1.64B | 12.24%511.4M | 3.51%292.91M | 17.82%403.93M | 7.67%430.07M | 6.14%1.48B | 2.35%455.65M | 7.22%282.97M | -1.92%342.85M |
Selling and administrative expenses | -39.81%1.3B | -19.27%10.8B | 0.79%3.66B | -29.70%2.17B | -14.83%2.82B | -35.80%2.15B | 11.76%13.38B | -17.92%3.63B | 21.48%3.08B | 10.18%3.31B |
-Selling and marketing expense | -39.81%1.3B | -24.67%8.94B | -15.14%1.81B | -29.70%2.17B | -14.83%2.82B | -35.80%2.15B | 12.19%11.87B | -29.96%2.13B | 21.48%3.08B | 10.18%3.31B |
-General and administrative expense | ---- | 23.30%1.86B | ---- | ---- | ---- | ---- | 8.44%1.51B | ---- | ---- | ---- |
Research and development costs | -5.65%211M | 10.34%932.54M | -46.21%158.18M | 3.49%260.37M | 71.07%290.36M | 72.31%223.64M | 63.89%845.18M | 188.15%294.07M | 35.56%251.58M | 39.34%169.74M |
Depreciation and amortization | 23.66%55M | 6.27%214.24M | 52.34%67.16M | 24.75%54.08M | -15.14%48.52M | -21.94%44.48M | 3.65%201.6M | -11.17%44.08M | -11.75%43.35M | 17.47%57.18M |
-Depreciation | 23.66%55M | 6.27%214.24M | 52.34%67.16M | 24.75%54.08M | -15.14%48.52M | -21.94%44.48M | 3.65%201.6M | -11.17%44.08M | -11.75%43.35M | 17.47%57.18M |
Other operating expenses | -21.20%1.19B | 24.88%5.13B | 301.52%498.85M | 8.95%1.62B | 4.19%1.5B | 5.71%1.51B | -0.78%4.1B | -80.82%-247.54M | 3.83%1.49B | -5.32%1.44B |
Operating profit | -88.23%197M | -93.21%416.28M | -438.59%-1.43B | -216.24%-400.76M | -83.96%574.63M | -6.15%1.67B | -10.84%6.13B | -51.57%422.92M | -83.44%344.78M | 259.45%3.58B |
Net non-operating interest income (expenses) | 44.53%-3M | 13.06%-19.42M | -255.38%-8.98M | 54.56%-2.44M | 71.30%-2.59M | 0.00%-5.41M | -83.01%-22.33M | -9.87%-2.53M | -86.29%-5.37M | -156.96%-9.03M |
Non-operating interest income | --0 | 11.31%1.64M | 28.23%795K | 458.55%849K | -116.16%-91K | -35.92%91K | 37.78%1.48M | 50.85%620K | -3.80%152K | 15.13%563K |
Non-operating interest expense | -45.44%3M | -11.55%21.06M | 210.62%9.77M | -40.42%3.29M | -73.93%2.5M | -0.92%5.5M | 79.36%23.81M | 16.09%3.15M | 81.61%5.52M | 139.64%9.6M |
Net investment income | -112.68%-50M | 274.11%1.16B | 99.50%444.75M | 92.03%-130.68M | -63.81%454.63M | -16.38%394.37M | -75.99%310.89M | -76.81%222.93M | -1,500.61%-1.64B | 577.73%1.26B |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | 54.08%-113M | -18.48%-541.87M | 63.93%-65.33M | -1,618.25%-25.54M | -55.45%-204.93M | -68.50%-246.07M | -340.21%-457.33M | -389.34%-181.15M | 103.94%1.68M | -479.08%-131.83M |
Special income (charges) | 81.56%-3M | 60.39%-31.89M | 3.61%-6.48M | -289.81%-3.4M | 92.14%-5.73M | -16.27M | -81.79%-80.5M | 78.30%-6.73M | 52.09%-873K | -1,598.90%-72.9M |
Less:Other special charges | -81.56%3M | -60.39%31.89M | -3.61%6.48M | 289.81%3.4M | --5.73M | --16.27M | 81.79%80.5M | -78.30%6.73M | -52.09%873K | ---- |
Other non-operating income (expenses) | -1,578.32%-12M | 85.15%-7.21M | -58.48%1.01M | 99.55%-215K | -170.32%-7.29M | -266.67%-715K | -1,299.01%-48.54M | 229.66%2.42M | -1,521.32%-48.07M | -292.29%-2.7M |
Income before tax | -99.33%12M | -83.23%978.97M | -333.03%-1.07B | 58.59%-558.04M | -82.61%803.73M | -14.44%1.8B | -27.21%5.84B | -74.06%457.87M | -162.55%-1.35B | 301.67%4.62B |
Income tax | -85.24%97M | -69.82%580.64M | -356.67%-305.82M | 71.15%-109.54M | -76.84%338.6M | -9.04%657.4M | -20.90%1.92B | -73.09%119.15M | -155.30%-379.71M | 288.35%1.46B |
Net income | -107.35%-84M | -89.82%398.33M | -324.72%-761.17M | 53.67%-448.5M | -85.29%465.13M | -17.26%1.14B | -29.96%3.91B | -74.38%338.73M | -165.93%-968.04M | 308.14%3.16B |
Net income continuous operations | -107.44%-85M | -89.82%398.33M | -324.72%-761.17M | 53.67%-448.5M | -85.29%465.13M | -17.26%1.14B | -29.96%3.91B | -74.38%338.73M | -165.93%-968.04M | 308.14%3.16B |
Noncontrolling interests | 0 | 0 | 0 | 0 | ||||||
Net income attributable to the company | -107.35%-84M | -89.82%398.33M | -324.72%-761.17M | 53.67%-448.5M | -85.29%465.13M | -17.26%1.14B | -29.96%3.91B | -74.38%338.73M | -165.93%-968.04M | 308.14%3.16B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -107.35%-84M | -89.82%398.33M | -324.72%-761.17M | 53.67%-448.5M | -85.29%465.13M | -17.26%1.14B | -29.96%3.91B | -74.38%338.73M | -165.93%-968.04M | 308.14%3.16B |
Gross dividend payment | ||||||||||
Basic earnings per share | -107.41%-1.54 | -89.82%7.24 | -324.51%-13.83 | 53.58%-8.17 | -85.26%8.47 | -17.28%20.77 | -29.96%71.12 | -74.37%6.16 | -165.94%-17.6 | 308.32%57.45 |
Diluted earnings per share | -107.41%-1.54 | -89.82%7.24 | -324.72%-13.8342 | 53.58%-8.17 | -85.29%8.4536 | -17.28%20.77 | -29.96%71.12 | -74.38%6.1563 | -165.96%-17.6 | 308.32%57.45 |
Dividend per share | 0 | 5.88%9 | 11.76%4.75 | 0 | 0.00%4.25 | 0 | 112.50%8.5 | 112.50%4.25 | 0 | 112.50%4.25 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |